Registry of Asthma Patients Initiating DUPIXENT®


About this study

The purpose of this study is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life. This includes characterization of patient demographics, and patient baseline characteristics (eg, prior medications and procedures, medical history, asthma history, weight, height). T

Additionally to characterize real-world use patterns, safety, and long-term effectiveness of DUPIXENT® for asthmam and to assess effectiveness on comorbid type 2 inflammatory conditions in asthma patients treated with DUPIXENT® .

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

- Willing and able to comply with the required clinic visits, study procedures and assessments.
- Able to understand and complete study-related questionnaires.
- Provide signed informed consent; for patients under the age of 18, both parental (legal guardian) consent and patient assent are required.
- Initiating treatment with DUPIXENT® for a primary indication of asthma according to the country-specific prescribing information.

Exclusion Criteria:

- Patients who have a contraindication to DUPIXENT® according to the country-specific prescribing information.
- Treatment with dupilumab within 6 months before the screening visit, or within 6 months of the baseline visit if the screening and baseline occur on the same day
- Any condition that, in the opinion of the investigator, may interfere with patient's ability to participate in the study or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments.

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Eligibility last updated 6/23/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Joseph Skalski, M.D.

Closed for enrollment

Contact information:

Christopher Roberts

(507) 284-9946

More information


Publications are currently not available

Mayo Clinic Footer